Pheochromocytoma risk factors: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) |
Ifrah Fatima (talk | contribs) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pheochromocytoma}} | {{Pheochromocytoma}} | ||
{{CMG}}; {{AE}} {{MAD}} | {{CMG}}; {{AE}} {{MAD}} {{IF}} | ||
==Overview== | ==Overview== | ||
The most potent risk factor for pheochromocytoma is a family history of [[Multiple endocrine neoplasia|multiple endocrine neoplasias,]] [[Von Hippel-Lindau disease]], [[Neurofibromatosis type I|neurofibromatosis type 1]], [[Paraganglioma|hereditary paraganglioma syndromes]]. | |||
==Risk Factors== | ==Risk Factors== | ||
The most potent risk factor in the development of pheochromocytoma is a family history of [[Multiple endocrine neoplasia|multiple endocrine neoplasias,]] [[Von Hippel-Lindau disease]], [[Neurofibromatosis type I|neurofibromatosis type 1]] or [[Paraganglioma|hereditary paraganglioma syndromes]]. | |||
* | ===Common Risk Factors=== | ||
*Common risk factors in the development of pheochromocytoma include harboring the following genes: | |||
**[[RET gene|RET]] gene ([[MEN, type 2a|MEN 2A]], [[Multiple endocrine neoplasia type 2|MEN 2B]] [[Syndrome|syndromes]]) | |||
**[[NF1|NF1 gene]] | |||
**[[Von Hippel-Lindau tumor suppressor|VHL gene]] ([[Von Hippel-Lindau disease|VHL disease]]) | |||
**[[SDHD]], [[SDHB]], and [[SDHC]] genes of the [[Mitochondrial|mitochondrial complex]] <ref name="pmid15883706">{{cite journal| author=Gimm O| title=Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. | journal=Fam Cancer | year= 2005 | volume= 4 | issue= 1 | pages= 17-23 | pmid=15883706 | doi=10.1007/s10689-004-5740-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15883706 }} </ref> | |||
=== | ===Less Common Risk Factors=== | ||
*Less common risk factors in the development of pheochromocytoma include harboring the following genes: | |||
**[[SDHA]] | |||
**[[SDHAF2]] | |||
** [[TMEM127]] (transmembrane protein 127) | |||
** [[MAX (gene)|MAX]] (myc-associated factor X) | |||
** [[Fumarate hydratase|FH]] (fumarate hydratase) | |||
* [[ | ** [[PDH complex|PDH1]], PDH2 (pyruvate dehydrogenase) | ||
* [[ | ** [[Hypoxia inducible factors|HIF1alpha]] (hypoxia-inducible factor) | ||
* | ** [[MDH1|MDH2]] (malate dehydrogenase) | ||
** KIF1Bß (kinesin family member) genes. <ref>{{cite book | last = Jameson | first = J | title = Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK | publisher = McGraw-Hill Medical | location = New York | year = 2017 | isbn = 978-1260128857 }} </ref> | |||
* [[ | |||
* | |||
* [[ | |||
* [[ | |||
* | |||
* | |||
==References== | ==References== | ||
Latest revision as of 00:32, 25 July 2020
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma risk factors On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma risk factors |
|
Risk calculators and risk factors for Pheochromocytoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2] Ifrah Fatima, M.B.B.S[3]
Overview
The most potent risk factor for pheochromocytoma is a family history of multiple endocrine neoplasias, Von Hippel-Lindau disease, neurofibromatosis type 1, hereditary paraganglioma syndromes.
Risk Factors
The most potent risk factor in the development of pheochromocytoma is a family history of multiple endocrine neoplasias, Von Hippel-Lindau disease, neurofibromatosis type 1 or hereditary paraganglioma syndromes.
Common Risk Factors
- Common risk factors in the development of pheochromocytoma include harboring the following genes:
Less Common Risk Factors
- Less common risk factors in the development of pheochromocytoma include harboring the following genes:
References
- ↑ Gimm O (2005). "Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx". Fam Cancer. 4 (1): 17–23. doi:10.1007/s10689-004-5740-1. PMID 15883706.
- ↑ Jameson, J (2017). Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK. New York: McGraw-Hill Medical. ISBN 978-1260128857.